{'fraction_non_alphanumeric': 0.025252525252525252, 'fraction_numerical': 0.0, 'mean_word_length': 5.685393258426966, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Vasopressin: novel roles for a new hormone – Emerging therapies in cardiometabolic and renal diseases

Disturbances of the vasopressin system have been known for several decades to play a main role in the rare diseases diabetes insipidus (no production of vasopressin or renal insensitivity) and syndrome of inappropriate ADH excess (SIADH) (excess secretion). The current symposium was launched because of new insights about important roles for high vasopressin secretion in the pathogenesis of cardiometabolic (i.e. diabetes, metabolic syndrome and cardiovascular disease) and renal diseases.